Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02911714 · ClinicalTrials.gov registry record · Phase 1
Contrast-Enhanced Ultrasound for Kidney Transplant
A Phase 1 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02911714 is a Phase 1 study that was terminated before completion, run by University of Utah. The registered enrollment target is 20 participants.
The verdict
NCT02911714, a Phase 1 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Contrast-enhanced ultrasound (CEUS) is a promising non-invasive imaging tool that may aid in the early detection of kidney transplant complications, such as delayed graft function (DGF) and acute allograft rejection. The technique uses an intravenous contrast agent to improve organ visualization with standard duplex ultrasound equipment. A number of FDA-approved agents, including Optison, Definity and Lumason are widely used to improve visualization in technically limited echocardiograms, and Lumason was recently approved for contrast-enhanced ultrasound of the liver. The specific aims of this study are to: develop, implement and refine a contrast-enhanced ultrasound protocol using Lumason to safely maximize kidney allograft visualization; determine associations between contrast-enhanced ultrasound and patterns of allograft injury consistent with delayed graft function; and to compare contrast-enhanced ultrasound with duplex ultrasound for differentiating acute rejection from other causes of dysfunction.
Interventions
- DRUG Lumason Contrast-Enhanced Ultrasound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-02-21 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02911714
The ClinicalTrials.gov registry entry for NCT02911714 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lumason Contrast-Enhanced Ultrasound is the first listed.
NCT02911714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02911714 about?
NCT02911714 is a clinical study titled "Contrast-Enhanced Ultrasound for Kidney Transplant". Contrast-enhanced ultrasound (CEUS) is a promising non-invasive imaging tool that may aid in the early detection of kidney transplant complications, such as delayed graft function (DGF) and acute allograft rejection. The technique uses an intravenous contrast agent to improve organ visualization wit...
What is the current status of trial NCT02911714?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-02-21. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT02911714?
The interventions under investigation include: Lumason Contrast-Enhanced Ultrasound (DRUG).
Who is sponsoring clinical trial NCT02911714?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.